PMID- 22683823
OWN - NLM
STAT- MEDLINE
DCOM- 20120816
LR  - 20220330
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 93
IP  - 11
DP  - 2012 Jun 15
TI  - Review of cytomegalovirus infection findings with mammalian target of rapamycin 
      inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
PG  - 1075-85
LID - 10.1097/TP.0b013e31824810e6 [doi]
AB  - Cytomegalovirus (CMV) infection and disease are major complications in the renal 
      transplant recipient. The occurrence of CMV is associated with acute rejection, 
      allograft dysfunction, significant end-organ disease, and mortality. Several 
      clinical studies have indicated that the use of certain immunosuppressive drugs 
      can delay the reconstitution of CMV-specific cell-mediated immune responses, 
      thereby leading to uncontrolled CMV replication. Accumulating evidence indicates, 
      however, that the use of the mammalian target of rapamycin (mTOR) inhibitors, 
      sirolimus, and everolimus, may decrease the incidence and severity of CMV 
      infection in renal transplant recipients. The purpose of this article is to 
      review CMV infection data from randomized clinical trials that investigated the 
      use of sirolimus- and everolimus-based treatment regimens in de novo renal 
      transplantation. The mTOR inhibitor clinical trials included were primarily 
      identified using biomedical literature database searches, with additional studies 
      added at the authors' discretion. This review will summarize these studies to 
      discuss whether mTOR inhibitor-based immunosuppressive therapy can reduce the 
      magnitude of CMV-related complications in the de novo renal transplantation 
      setting.
FAU - Nashan, Bjorn
AU  - Nashan B
AD  - Department of Hepatobiliary Surgery and Visceral Transplantation, University 
      Hospital Hamburg Eppendorf, Hamburg, Germany. nashan@uke.uni-hamburg.de
FAU - Gaston, Robert
AU  - Gaston R
FAU - Emery, Vincent
AU  - Emery V
FAU - Saemann, Marcus D
AU  - Saemann MD
FAU - Mueller, Nicolas J
AU  - Mueller NJ
FAU - Couzi, Lionel
AU  - Couzi L
FAU - Dantal, Jacques
AU  - Dantal J
FAU - Shihab, Fuad
AU  - Shihab F
FAU - Mulgaonkar, Shamkant
AU  - Mulgaonkar S
FAU - Seun Kim, Yu
AU  - Seun Kim Y
FAU - Brennan, Daniel C
AU  - Brennan DC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Cytomegalovirus/drug effects
MH  - Cytomegalovirus Infections/etiology/*prevention & control
MH  - Everolimus
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology/*therapeutic use
MH  - *Kidney Transplantation
MH  - Postoperative Complications/*prevention & control
MH  - Sirolimus/*analogs & derivatives/pharmacology/*therapeutic use
EDAT- 2012/06/12 06:00
MHDA- 2012/08/17 06:00
CRDT- 2012/06/12 06:00
PHST- 2012/06/12 06:00 [entrez]
PHST- 2012/06/12 06:00 [pubmed]
PHST- 2012/08/17 06:00 [medline]
AID - 00007890-201206150-00002 [pii]
AID - 10.1097/TP.0b013e31824810e6 [doi]
PST - ppublish
SO  - Transplantation. 2012 Jun 15;93(11):1075-85. doi: 10.1097/TP.0b013e31824810e6.